C. M. Rooney, C. A. Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey et al., Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients, Blood, vol.92, pp.1549-1555, 1998.

A. Gustafsson, V. Levitsky, J. Z. Zou, T. Frisan, T. Dalianis et al., , 2000.

. Epstein-barr, virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-speciWc cytotoxic T cells, Blood, vol.95, pp.807-814

B. Savoldo, J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez et al., Treatment of solid organ transplant recipients with autologous Epstein-Barr virus-speciWc cytotoxic T lymphocytes (CTLs), Blood, vol.108, pp.2942-2949, 2006.

H. J. Kolb, J. Mittermuller, C. Clemm, E. Holler, G. Ledderose et al., Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients, Blood, vol.76, pp.2462-2465, 1990.

B. Dreno, J. M. Nguyen, A. Khammari, M. C. Pandolwno, M. H. Tessier et al., Randomized trial of adoptive transfer of melanoma tumor-inWltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunol Immunother, vol.51, pp.539-546, 2002.

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu et al., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, vol.298, pp.850-854, 2002.

N. Labarriere, M. C. Pandolwno, N. Gervois, A. Khammari, M. H. Tessier et al., Therapeutic eYcacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunol Immunother, vol.51, pp.532-538, 2002.

P. Guillaume, D. F. Legler, N. Boucheron, M. A. Doucey, J. C. Cerottini et al., Soluble major histocompatibility complexpeptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis, J Biol Chem, vol.278, pp.4500-4509, 2003.

M. Cebecauer, P. Guillaume, P. Hozak, S. Mark, H. Everett et al., Soluble MHC-peptide complexes induce rapid death of CD8 + CTL, J Immunol, vol.174, pp.6809-6819, 2005.

M. Cobbold, N. Khan, B. Pourgheysari, S. Tauro, D. Mcdonald et al., Adoptive transfer of cytomegalovirus-speciWc CTL to stem cell transplant patients after selection by HLA-peptide tetramers, J Exp Med, vol.202, pp.379-386, 2005.

M. Bodinier, M. A. Peyrat, C. Tournay, F. Davodeau, F. Romagne et al., EYcient detection and immunomagnetic sorting of speciWc T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat Med, vol.6, pp.707-710, 2000.

N. Labarriere, N. Gervois, A. Bonnin, R. Bouquie, F. Jotereau et al., PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting, Cancer Immunol Immunother, vol.57, pp.185-195, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00167752

N. Gervois, F. Heuze, E. Diez, and F. Jotereau, Selective expansion of a speciWc anti-tumor CD8 + cytotoxic T lymphocyte clone in the bulk culture of tumor-inWltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements, Eur J Immunol, vol.20, pp.825-831, 1990.

F. Jotereau, M. C. Pandolwno, D. Boudart, E. Diez, B. Dreno et al., LeMevel B (1991) High-fold expansion of human cytotoxic T-lymphocytes speciWc for autologous melanoma cells for use in immunotherapy, J Immunother, vol.10, pp.405-411, 1991.

D. Valmori, J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard et al., Enhanced generation of speciWc tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J Immunol, vol.160, pp.1750-1758, 1998.

A. L. Cox, J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow et al., IdentiWcation of a peptide recognized by Wve melanoma-speciWc human cytotoxic T cell lines, Science, vol.264, pp.716-719, 1994.

Y. Guilloux, S. Lucas, V. G. Brichard, A. Van-pel, C. Viret et al., A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene, J Exp Med, vol.183, pp.1173-1183, 1996.

V. Vignard, B. Lemercier, A. Lim, M. C. Pandolwno, Y. Guilloux et al., Adoptive transfer of tumor-reactive Melan-A-speciWc CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-speciWc T cells, J Immunol, vol.175, pp.4797-4805, 2005.

N. Gervois, N. Labarriere, L. Guiner, S. Pandolwno, M. C. Fonteneau et al., High avidity melanoma-reactive cytotoxic T lymphocytes are eYciently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells, Clin Cancer Res, vol.6, pp.1459-1467, 2000.

D. J. Cole, M. C. Wilson, L. Rivoltini, M. Custer, and M. I. Nishimura, T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-inWltrating lymphocytes, Cancer Res, vol.57, pp.5320-5327, 1997.

A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger et al., Phase I study of adoptive T-cell therapy using antigen-speciWc CD8 + T cells for the treatment of patients with metastatic melanoma, J Clin Oncol, vol.24, pp.5060-5069, 2006.

N. Labarriere, L. Bretaudeau, N. Gervois, M. Bodinier, G. Bougras et al., Apoptotic bodyloaded dendritic cells eYciently cross-prime cytotoxic T lymphocytes speciWc for NA17-A antigen but not for Melan-A/MART-1 antigen, Int J Cancer, vol.101, pp.280-286, 2002.

S. Yang, G. P. Linette, S. Longerich, and F. G. Haluska, Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2 M is correlated to TCR avidity, J Immunol, vol.169, pp.531-539, 2002.

M. Cebecauer, P. Guillaume, S. Mark, O. Michielin, N. Boucheron et al., , 2005.

, CD8 + cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers, J Biol Chem, vol.280, pp.23820-23828

S. Freitag, L. Trong, I. Klumb, L. Stayton, P. S. Stenkamp et al., Structural studies of the streptavidin binding loop, Protein Sci, vol.6, pp.1157-1166, 1997.

V. Dutoit, V. Rubio-godoy, P. Y. Dietrich, A. L. Quiqueres, V. Schnuriger et al., Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-speciWc cytolytic T lymphocytes show superior antitumor activity, Cancer Res, vol.61, pp.5850-5856, 2001.

E. M. Creagh, H. Conroy, and S. J. Martin, Caspase-activation pathways in apoptosis and immunity, Immunol Rev, vol.193, pp.10-21, 2003.

M. E. Peter and P. H. Krammer, The CD95(APO-1/Fas) DISC and beyond, vol.10, pp.26-35, 2003.

K. Gulow, M. Kaminski, K. Darvas, D. Suss, M. Li-weber et al., HIV-1 trans-activator of transcription substitutes for oxidative signaling in activation-induced T cell death, J Immunol, vol.174, pp.5249-5260, 2005.

M. Knabel, T. J. Franz, M. Schiemann, A. Wulf, B. Villmow et al., Reversible MHC multimer staining for functional isolation of T-cell populations and eVective adoptive transfer, Nat Med, vol.8, pp.631-637, 2002.

J. Neudorfer, B. Schmidt, K. M. Huster, F. Anderl, M. Schiemann et al., Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor-and virus-derived antigens, J Immunol Meth, vol.320, pp.119-131, 2007.